Subject is permanently discontinued from further trial treatment administration.No subsequent dosing Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of drug administration. 124 Abbreviated Title: GBM Pembro HSPPC Version Date: 03/26/2024 16.9 MD ANDERSON SYMPTOM INVENTORY (MDASI-BT) This questionnaire is a separate document. 125 Abbreviated Title: GBM Pembro HSPPC Version Date: 03/26/2024 16.10 CCR REPORTABLE EVENT FORM (REF) NCI Protocol #: Protocol Title: Report version: (select one) ☐ Initial Report ☐ Follow-up Site Principal Investigator: Date site PI was notified of the problem: Date of problem: If delay in reporting to the coordinating center, please explain: Location of problem: (e.g., patient’s home, doctor’s office ) Description of Subject Does this problem apply to a subject? ☐ yes ☐ not applicable (more than one subject is involved) If yes, enter details below: Subject ID: (do not use medical record number) Sex: ☐Male ☐ Female Age: 126 Abbreviated Title: GBM Pembro HSPPC Version Date: 03/26/2024 Diagnosis: Name the problem: (select all that apply) ☐ Specimen collection issue ☐ Informed consent issue ☐ Ineligible for enrollment ☐ Breach of PII ☐ Other, briefly state the nature of the problem: Detailed Description of the problem: (Include any relevant treatment, outcomes or pertinent history): What are you reporting? ☐ unanticipated problem ☐ death ☐ non-compliance (other than a protocol deviation) ☐ protocol deviation ☐ new information that might affect the willingness of subjects to enroll or continue participation in this study If interventional or expanded access study, please answer the following questions about your site: 127 Abbreviated Title: GBM Pembro HSPPC Version Date: 03/26/2024 How many participants are still receiving the study intervention? How many participants completed study interventions but remain in follow up? How many participants are enrolled but not yet receiving study interventions?